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Abstract Nephropathic cystinosis (NC) is an autosomal
recessive disorder caused by mutations of the CTNS gene
that encodes for a cystine transmembrane transporter. Several
mutations have been described in the coding and promoter
regions of the CTNS gene in affected individuals. We
selected three patients with NC from two unrelated families,
in whom sequence analysis of the CTNS gene detected only
one or no mutations. Total RNAwas isolated from peripheral
blood mononuclear cells or fibroblasts and CTNS transcripts
were analyzed. We observed a skipping of exon 5 (85 bp) in
two siblings and an intron 9 retention of 75 bp associated
with partial replication of exon 9 in the third patient.
Genomic DNA analysis of intron regions surrounding exon
5 showed a point mutation in the hypothetical lariat branch
site of intron 4 at position –24 (c.141–24 T>C) in the first
two patients and a duplication of 266 bp including a part of
exon and intron 9 in the third patient. Analysis of CTNS
gene transcripts allowed identification of mutations in
patients in whom CTNS mutations could not be detected
by traditional DNA sequencing. These results support the
hypothesis that cystinosis is a monogenic disorder.
Keywords Nephropathic cystinosis .CTNS gene . Splicing
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Introduction
Nephropathic cystinosis (NC) (OMIN 219800) is a rare
autosomal recessive disorder (incidence in 1:100,000–
200,000 live births), which presents with renal proximal
tubular dysfunction (Fanconi syndrome) during infancy and
progresses to end-stage renal failure during the first decade
of life if not treated with cysteamine [1]. Over time, patients
with NC also present with dysfunction of several organs,
including eyes, thyroid, liver, pancreas, male gonad,
muscles, and brain [2]. NC is caused by mutations in the
CTNS gene [3]. It encodes for cystinosin, an amino-acid-
cystine carrier that is predicted to have seven transmem-
brane domains and is primarily expressed in the lysosomal
membrane [4]. Lack of cystinosin activity causes cystine
accumulation and results in formation of intralysosomal
cystine crystals. Approximately 10–20% of CTNS tran-
scripts encode for a second cystinosin isoform, termed
cystinosin-LKG, which results from an alternative splicing
of exon 12 and is expressed in the plasma membrane and
other cytosolic vesicles, in addition to lysosomes [5].
The CTNS gene maps to chromosome 17p13 and is
composed of 12 exons, with the start codon located on exon
3 [3]. The most common CTNS mutation in northern
Europe is a 57-kb deletion that originated in Germany
around AD 500 [1]. To date, more than 90 mutations have
been described in the coding region or flanking intronic
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regions of the gene, as well as in the CTNS promoter, in
patients with cystinosis. Of these, approximately 70
mutations cause NC. These include small deletions or
insertions, missense or nonsense mutations, and splicing
mutations [3, 6–13].
In clinical practice, the diagnosis of NC is sustained by
the demonstration of increased intraleucocyte cystine
levels. Genetic tests have primarily a confirmatory value
and allow for genetic counseling. Evidence suggests that
NC is a monogenic disease, although the mutation detection
rate is not 100%. Shotelersuk et al., for example, sequenced
the CTNS gene in 108 American patients with NC and
failed to detect mutations in 19% of affected individuals
[6]. The CTNS promoter was, however, not analyzed in their
study. Similar studies that also included the promoter region
showed only heterozygous or no mutations in 18% of 46
Italian patients and in 6% of 108 French patients [9, 11].
In this work, we studies CTNS gene transcripts in three
patients with NC from two families to search for mutations
that were not detected at the genomic level.
Patients and methods
Patients
Among 49 Dutch patients with NC from 44 different
families, we selected three patients in whom sequence
analysis failed to show homozygous or double heterozy-
gous mutations in the CTNS gene (coding regions, intron/
exon boundaries, or promoter region). Clinical data of these
patients are summarized in Table 1. The diagnosis of NC
was established in all patients by demonstration of
increased intraleucocyte cystine levels and corneal cystine
crystal depositions. Informed consent was obtained to
perform the additional genetic studies included in this work.
Peripheral blood mononuclear cell isolation
and fibroblasts cell lines
Anticoagulated whole blood samples were diluted with
phosphate-buffered saline (PBS) (1:1), layered over Ficoll
Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA),
and centrifuged at 1,800 g for 20 min at room temperature.
The peripheral blood mononuclear cell (PBMC) layer was
removed and washed twice with PBS following two
centrifugation steps at 250 g for 10 min. RNA studies were
performed in patient 3 on a previously established
fibroblast cell line from that patient [14].
Reverse transcriptase–polymerase chain reaction (RT-PCR)
analysis
Total RNA was extracted from PBMCs or fibroblasts using
TRIzol® reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA). RNAwas reverse-transcribed into complementary
DNA (cDNA) using a first-strand cDNA synthesis kit (Roche
Diagnostics, Mannheim, Germany). CTNS transcripts were
amplified by PCR adding Taq DNA polymerase, PCR buffer
with magnesium chloride (MgCl2), deoxyribonucleotide
triphosphate (dNTP) (Invitrogen Life Technologies), and
primers (Sigma-Aldrich, St. Louis, MO, USA) in accordance
with the manufacturers’ instructions. Primers and PCR
conditions for CTNS amplification are described in Table 2.
PCR products were analyzed using a 1.5% agarose gel with
GelRed™ staining (Biotium Inc., Hayward, CA, USA).
PCR fragments were extracted and purified with gel
extraction kit (QIAGEN, Milan, Italy). Transcript sequencing
was performed using primers detailed in Table 2 and dye
terminator cycles sequencing (DTCS) Quick Start Mix
(Beckman Coulter, Brea, CA, USA) at following conditions:
96°C for 30 s, 53°C for 30 s, and 60°C for 240 s for 37
cycles. After purification, samples were sequenced on a
CEQ2000XL DNA Analysis System (Beckman Coulter).
Genomic DNA analysis
Genomic DNA was extracted from anticoagulated whole
peripheral blood by QIAamp DNA blood kit (QIAGEN) in
accordance with the manufacturer’s instructions. The CTNS
gene was amplified using primers and PCR conditions
detailed in Table 2. Direct sequencing was performed with
the primers described in Table 2 and DTCS Quick Start
Mix (Beckman Coulter) at conditions detailed above.
Samples were sequenced on a CEQ2000XL DNA Analysis
System (Beckman Coulter).
Patient 1 Patient 2 Patient 3
Gender F M F
Age of diagnosis (months) 41 48 18
Age at ESRF (years) 12 10.3 14.2
Intraleucocyte cystine
(nmol ½ cystine/mg protein)
5.2 7.8 9






Table 1 Patient characteristics
M male, F female, ESRF
end-stage renal failure
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Results
This study was performed on three patients with a clinical
diagnosis of NC who had been previously screened for the
CTNS gene mutations that revealed only one or no mutated
alleles. Patients 1 and 2 are siblings. Previous sequence
analysis had shown a heterozygous 57-kb deletion. No
mutation was found on the other allele. To identify the
second CTNS mutation, gene transcripts were analyzed
from total RNA extracted from PBMCs. The PCR reaction
yielded a 1,456-bp fragment spanning exons 2–12 that
contained a 85-bp deletion corresponding to the entire exon
5 (Fig. 1). To highlight this deletion, CTNS transcripts were
amplified using primers spanning exons 3–7 and were
resolved by agarose gel electrophoresis, demonstrating a
shorter band compared with control cDNA (Fig. 1).
Skipping of exon 5 in these two patients causes a frameshift
at position 141 bp, with a premature stop codon at position
160 bp. This splicing defect was further analyzed by
sequencing the flanking intronic regions up to 300 bp
upstream and downstream of exon 5. The analysis showed
a point mutation at position –24 bp (c.141–24 T>C) of
intron 4 that was not detected in 100 control chromosomes.
The predicted protein generated by exon 5 skipping was
truncated at position 53 after introducing six modified
amino acids at the carboxy terminal end (wild-type
cystinosin: 367 amino acids).
Genomic DNA analysis failed to reveal any CTNS gene
mutations in patient 3. CTNS transcripts were amplified
from skin fibroblasts and demonstrated a homozygous
duplication located in the exon 9 region (Fig. 1). Specifi-
cally, the messenger RNA (mRNA) sequence of exon 9 was
followed by a 75-bp sequence corresponding to a portion of
intron 9, located 118 bp downstream to the exon donor
splicing site and by a repeat sequence of the last 73 bp of
exon 9. At the genomic level, this transcript corresponded
Amplified products Product length (bp) Primer sequences PCR conditions
Exon regions
2–12 1,456 Fw 5′–gagacgctgagagaacctttgc–3′ a.t.: 64°C
Rv 5′–gagtggtctcctctgtccgc–3′ e.t.: 90 s
3–7 382 Fw 5′–ccctgaagctcgtagagaaatg–3′ a.t.: 60°C
Rv 5′–gatggaccaggccacaaagtag–3′ e.t.: 30 s
7–12 842 Fw 5′–ggatctactttgtggcctggt–3′ a.t.: 60°C
Rv 5′–gagtggtctcctctgtccgc–3′ e.t.: 60 s
Intron regions
4–5 310 Fw 5′–ctgattaagacaggaaggcc–3′ a.t.: 56°C
Rv 5′–acctagcatttccctaccc–3′ e.t.: 30 s
8–9 585 Fw 5′–gccttgcctgccctacatctc–3′ a.t.: 63°C
Rv 5′–acttcactcatccttggagccc–3′ e.t.: 60 s
Table 2 Primer sequences and
polymerase chain reaction
(PCR) amplification conditions
Fw forward, Rv reverse, a.t.
annealing temperature,
e.t. extension time
Fig. 1 Detected DNA and messenger RNA (mRNA) changes. a
Patients 1 and 2 had a T>C substitution at position –24, upstream of
exon 5 (c.141–24 T>C) that was not detected by standard sequencing.
This mutation causes a skipping of exon 5 in the CTNS gene
transcripts, as demonstrated by direct sequencing and agarose gel
electrophoresis after reverse transcriptase–polymerase chain reaction
(RT-PCR) amplification of the region spanning exons 3–7. The
smaller band (297 bp) corresponds to the amplicon lacking exon 5.
b Patient 3 had a duplication of the genomic DNA sequence
encompassing the last 73 bp of exon 9 and the first 193 bp of intron
9, shown in dark gray. This duplication causes an additional splicing
of the mRNA transcript, with the incorporation of a portion of intron 9
followed by a repeat sequence corresponding to the duplicated portion
of intron 9. By agarose gel electrophoresis using primers spanning
exons 7 to 12, a larger 990 bp band is observed
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to a duplication of the last 73 bp of exon 9 and the first
193 bp of intron 9, which introduces an additional splicing
site that removes the first 118 bp of intron 9. When
resolved on an agarose gel, the amplicon of patient 3
produced a larger band that included 148 additional
nucleotides (Fig. 1). The predicted protein was truncated
at position 232 by a frameshift that generated 5 mutated
amino acids, followed by a stop codon.
Discussion
In this work, two novel mutations in the CTNS gene were
detected by studying CTNS mRNA transcripts in patients in
whom traditional genomic sequencing failed to detect
mutations in one or both alleles. Specifically, a splicing
defect and a DNA duplication were identified. Analysis of
gene transcripts may be limited by tissue-specific expression
patterns. Fortunately, the CTNS gene is ubiquitously
expressed, and accumulation of increased cystine has been
demonstrated in various tissues and cell lines, including
fibroblasts, proximal tubular cells, and PBMCs [15–17].
In all our patients, the clinical diagnosis of NC was
confirmed by measuring intraleucocyte cystine levels. The
splicing defect in patients 1 and 2 was located in an intronic
region that is not routinely investigated (T>C substitution
24 bp upstream of the splicing acceptor site of intron 4).
This mutation is located at a hypothetical lariat branch site
and probably plays an important role in the splicing of exon
5. Lariat branch sites are crucial for appropriate splicing of
pre-mRNAs, and point mutations in these regions have
been shown to cause abnormal mRNA splicing [18–20].
The 266-bp DNA duplication in patient 3 could not be
detected using standard sequencing primers spanning exon
9 and its immediate neighboring intronic regions. In fact,
this is the first DNA duplication described in patients with
NC. Apart from point mutations and small insertion/
deletions, all other mutations involve larger deletions [3, 6].
With this study, mutations in the CTNS gene were
identified in all investigated Dutch patients, with the
exception of one individual from whom RNA material
was not available. Because the diagnosis of NC is
substantiated by very specific findings, such as increased
intraleucocyte cystine levels and corneal cystine crystals
depositions, failure to discover mutations in these patients
can be reasonably explained only by detection failures or
by the existence of a second cystinotic gene. Our findings
support the hypothesis that cystinosis is a monogenic
disorder and suggest that CTNS transcripts should be
studied when traditional genomic sequencing does not
allow mutation detection. In addition, cystinosin-LKG is
encoded by an alternative splicing of exon 12 and includes
sequences that are located in the originally described 3′
untranslated region of the gene [5]. Although we have
never observed mutations in this region (unpublished data),
we also systematically include in our sequencing protocol
the amplification of cystinosin-LKG-specific sequences.
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